Ignite Creation Date:
2024-05-06 @ 2:54 PM
Last Modification Date:
2024-10-26 @ 1:39 PM
Study NCT ID:
NCT04466189
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2020-07-13
First Post:
2020-07-07
Brief Title:
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
Sponsor:
National Cancer Center Korea
Organization:
National Cancer Center Korea
Study Overview
Official Title:
Prospective Cohort Study for Identifying Factors Predicting Clinical Outcomes of Pancreatic Cancer Patients Treated With Proton Beam Therapy
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pancreatic cancer is one of the few cancers whose survival rate has not improved significantly due to high local recurrence and systemic metastasis despite advances in diagnosis and treatment over the past 40 years And currently pancreatic cancer is the fifth leading cause of cancer-related death in Korea For this reason various anti-cancer therapies and radiotherapy have been tested to improve survival
Due to recent advances in radiotherapy technology proton beam therapy PBT is a promising treatment for pancreatic cancer because it can reduce radiation dose from surrounding normal tissue while maximizing radiation to tumor tissues due to the distinct physical properties of proton beam Low toxicity have been reported In addition retrospective analysis of pancreatic cancer patients n37 who performed proton therapy PBT from June 2013 to July 2016 showed promising therapeutic performance and less toxicity survival rate 193 months Grade 3 Toxicity 0 In addition gene polymorphisms of several genes CD44 CD166 XAF1 MMP9 MUC14 SMAD7 SMAD4 DPC RRM1 ERCC1 HER2 etc in pancreatic cancer have been reported to be associated with recurrence and prognosis
Due to recent advances in radiotherapy technology proton beam therapy PBT is a promising treatment for pancreatic cancer because it can reduce radiation dose from surrounding normal tissue while maximizing radiation to tumor tissues due to the distinct physical properties of proton beam Low toxicity have been reported In addition retrospective analysis of pancreatic cancer patients n37 who performed proton therapy PBT from June 2013 to July 2016 showed promising therapeutic performance and less toxicity survival rate 193 months Grade 3 Toxicity 0 In addition gene polymorphisms of several genes CD44 CD166 XAF1 MMP9 MUC14 SMAD7 SMAD4 DPC RRM1 ERCC1 HER2 etc in pancreatic cancer have been reported to be associated with recurrence and prognosis
Detailed Description:
Pancreatic cancer is one of the few cancers whose survival rate has not improved significantly due to high local recurrence and systemic metastasis despite advances in diagnosis and treatment over the past 40 years And currently pancreatic cancer is the fifth leading cause of cancer-related death in Korea For this reason various anti-cancer therapies and radiotherapy have been tested to improve survival
Due to recent advances in radiotherapy technology proton beam therapy PBT is a promising treatment for pancreatic cancer because it can reduce radiation dose from surrounding normal tissue while maximizing radiation to tumor tissues due to the distinct physical properties of proton beam Low toxicity have been reported In addition retrospective analysis of pancreatic cancer patients n37 who performed proton therapy PBT from June 2013 to July 2016 showed promising therapeutic performance and less toxicity survival rate 193 months Grade 3 Toxicity 0 In addition gene polymorphisms of several genes CD44 CD166 XAF1 MMP9 MUC14 SMAD7 SMAD4 DPC RRM1 ERCC1 HER2 etc in pancreatic cancer have been reported to be associated with recurrence and prognosis Therefore in this study a prospective cohort of pancreatic cancer patients treated with proton beam therapy was established to analyze local control survival recurrence toxicity proton treatment plan information gene expression information to analyze local control LC overall survival OS recurrence-free surival RFS and factors predicting treatment-related toxicity
Due to recent advances in radiotherapy technology proton beam therapy PBT is a promising treatment for pancreatic cancer because it can reduce radiation dose from surrounding normal tissue while maximizing radiation to tumor tissues due to the distinct physical properties of proton beam Low toxicity have been reported In addition retrospective analysis of pancreatic cancer patients n37 who performed proton therapy PBT from June 2013 to July 2016 showed promising therapeutic performance and less toxicity survival rate 193 months Grade 3 Toxicity 0 In addition gene polymorphisms of several genes CD44 CD166 XAF1 MMP9 MUC14 SMAD7 SMAD4 DPC RRM1 ERCC1 HER2 etc in pancreatic cancer have been reported to be associated with recurrence and prognosis Therefore in this study a prospective cohort of pancreatic cancer patients treated with proton beam therapy was established to analyze local control survival recurrence toxicity proton treatment plan information gene expression information to analyze local control LC overall survival OS recurrence-free surival RFS and factors predicting treatment-related toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None